Q’Apel Medical, Inc., a Fremont, Calif.-based neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, raised $22M in Series C funding.
The round included River Cities Capital, Soleus Capital, and incumbent investor Research Corporation Technologies (RCT). Scott Huennekens, former Chairman, CEO and President of Verb Surgical, and Carter McNabb, Managing Director, River Cities Capital, will join the Board of Directors.
Led by King Nelson, CEO, Q’Apel Medical Q’Apel Medical provides two core products: the Walrus Balloon Guide Catheter (BGC) system, and the Wahoo Control™ Catheter hybrid access system.
Walrus BGC is specifically designed to assist doctors in performing mechanical thrombectomy procedures on stroke patients.
The Wahoo Control™ Catheter is a dual-mode hybrid access system, providing two distinct operational modes – Tracking Mode and Support Mode. The physician controls the change of modes at any given moment during a clinical case. The hybrid nature of Wahoo reduces the need for multiple catheters in challenging procedures.
The products are already being utilized in over 130 hospital systems nationwide. In 2021, Q’Apel plans to significantly increase its manufacturing capacity, add additional head count and expand their product portfolio. At the same time, the company is in the process of acquiring CE certification, which will allow Q’Apel to expand into Europe later this year.